Literature DB >> 16946363

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.

David S Baldwin1, Anna Karina Trap Huusom, Eli Maehlum.   

Abstract

BACKGROUND: It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder. AIMS: To assess the efficacy of different doses of escitalopram in generalised anxiety disorder.
METHOD: Randomised, double-blind, placebo-controlled, fixed-dose, parallel-group, 12-week study, with 681 patients: placebo (n=139); escitalopram, 5 mg/day, (n=134); 10 mg/day (n=136); 20 mg/day (n=133); paroxetine, 20 mg/day (n=139).
RESULTS: Mean change in the primary efficacy measure was greater with escitalopram 10 and 20 mg than with placebo; 10 mg was more efficacious than paroxetine. Paroxetine was superior to placebo on some secondary measures, at some time points. Compared with placebo, more patients withdrew because of adverse events with escitalopram 20 mg and paroxetine.
CONCLUSIONS: Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day. Escitalopram 10 mg was more efficacious than paroxetine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946363     DOI: 10.1192/bjp.bp.105.012799

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

Review 1.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

Review 2.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2007-11-20

Review 3.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Authors:  Bret R Rutherford; Veronika S Bailey; Franklin R Schneier; Emily Pott; Patrick J Brown; Steven P Roose
Journal:  Depress Anxiety       Date:  2015-10-05       Impact factor: 6.505

Review 5.  Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.

Authors:  Angelina F Gomez; Abigail L Barthel; Stefan G Hofmann
Journal:  Expert Opin Pharmacother       Date:  2018-05-28       Impact factor: 3.889

Review 6.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 9.  Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Patricia Thieda; Richard A Hansen; Bradley N Gaynes; Angela Deveaugh-Geiss; Erin E Krebs; Kathleen N Lohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 10.  The cost effectiveness of pharmacological treatments for generalized anxiety disorder.

Authors:  Ifigeneia Mavranezouli; Nick Meader; John Cape; Tim Kendall
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.